AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15494457 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH (gonadotropin-releasing hormone) bolus iv injection
Number of subjects: 31
Study 12194665 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M APC Mini Twin bracket system
Number of subjects: 29
Study 12194665 — intervention group
Group type: COMPARATOR
Intervention: Transbond XT adhesive
Number of subjects: 29
Study 12194665 — intervention group
Group type: EXPERIMENTAL
Intervention: Inexperienced operators
Number of subjects: 29
Study 10455843 — intervention group
Group type: EXPERIMENTAL
Intervention: Buscopan 20 mg
Number of subjects: 45
Study 10455843 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 45
Study 7598238 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac tromethamine (KT) 60 mg IV 15 min after skin incision
Number of subjects: 30
Study 7598238 — intervention group
Group type: COMPARATOR
Intervention: Placebo i.v.
Number of subjects: 30
Study 2193555 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-methadone (0.573 mg)
Number of subjects: 120
Study 2193555 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-methadone (1.145 mg)
Number of subjects: 120
Study 2193555 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-methadone (0.573 mg) + metamizol (50 mg)
Number of subjects: 120
Study 2193555 — intervention group
Group type: COMPARATOR
Intervention: PCA (Patient-Controlled Analgesia)
Number of subjects: 120
Study 7364735 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine
Number of subjects: 38
Study 7364735 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 38
Study 30614717 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 1246
Study 30614717 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1246
Study 30614717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1246
Study 27801596 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) autoinjector
Number of subjects: 152
Study 27801596 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab, etanercept, and golimumab devices
Number of subjects: 152
Study 25366527 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing on a tilt table for 30 minutes per session, five times per week for 6 weeks
Number of subjects: 20
Study 25366527 — intervention group
Group type: COMPARATOR
Intervention: Not standing for 10 weeks followed by standing for 6 weeks
Number of subjects: 20
Study 23843569 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture (10 sessions, 3 sessions/week) on traditional Chinese acupoints
Number of subjects: 50
Study 21690627 — intervention group
Group type: EXPERIMENTAL
Intervention: abacavir-lamivudine (ABC-3TC)
Number of subjects: 269
Study 21690627 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir DF-emtricitabine (TDF-FTC)
Number of subjects: 269
Study 21690627 — intervention group
Group type: EXPERIMENTAL
Intervention: atazanavir-ritonavir (ATV-r)
Number of subjects: 269
Study 21690627 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz (EFV)
Number of subjects: 269
Study 21690627 — intervention group
Group type: EXPERIMENTAL
Intervention: VAT:TAT
Number of subjects: 269
Study 19533128 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective surgery for biliary atresia
Number of subjects: 0
Study 19533128 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation when necessary
Number of subjects: 0
Study 17162046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical atropine
Number of subjects: 57
Study 17162046 — intervention group
Group type: COMPARATOR
Intervention: Oral oxybutynin
Number of subjects: 57
Study 16211594 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (3.23 mg/day)
Number of subjects: 294
Study 16211594 — intervention group
Group type: COMPARATOR
Intervention: Levodopa (504 mg/day)
Number of subjects: 294
Study 16211594 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 294
Study 16211594 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 294
Study 15570147 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4% maltodextrin solution (CHO)
Number of subjects: 9
Study 15570147 — intervention group
Group type: COMPARATOR
Intervention: Water (PLA)
Number of subjects: 9
Study 11018576 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior change interventions, specific details not available.
Number of subjects: 0
Study 11018576 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative practitioner-participant relationship, specific details not available.
Number of subjects: 0
Study 8872730 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of image enhancement system during lithotripsy
Number of subjects: 81
Study 8872730 — intervention group
Group type: COMPARATOR
Intervention: Standard lithotripsy treatment without image enhancement
Number of subjects: 81
Study 2053765 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mg sustained release verapamil as a single dose
Number of subjects: 18
Study 2053765 — intervention group
Group type: COMPARATOR
Intervention: 360 mg sustained release verapamil as two divided doses
Number of subjects: 18
Study 6352209 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 6
Study 6352209 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed intermittent subcutaneous insulin infusion (30‐, 60‐, and 120‐min intervals)
Number of subjects: 6
Study 30080693 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightly replacement (NR) of lenses
Number of subjects: 0
Study 30080693 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning replacement (MR) of lenses
Number of subjects: 0
Study 30080693 — intervention group
Group type: EXPERIMENTAL
Intervention: Instillation of prophylactic antibiotic drops (AB) each morning/evening
Number of subjects: 0
Study 30080693 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily lens cleaning (LC) each morning
Number of subjects: 0
Study 30080693 — intervention group
Group type: COMPARATOR
Intervention: Control group (combined data)
Number of subjects: 0
Study 29072017 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at thirteen evil acupoints
Number of subjects: 74
Study 29072017 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (intravenous injection of aspartate ornithine and branched chain amino acids)
Number of subjects: 74
Study 29072017 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 74
Study 26019142 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1772
Study 26019142 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1772
Study 23867908 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericardiocentesis and extended pericardial drainage
Number of subjects: 0
Study 23867908 — intervention group
Group type: COMPARATOR
Intervention: Pericardiocentesis alone
Number of subjects: 0
Study 22098306 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pushing for 15-29 min (n=6589)
Number of subjects: 36832
Study 22098306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord artery pH <7.00
Number of subjects: 36832
Study 22098306 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pushing duration
Number of subjects: 36832
Study 19401125 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention
Number of subjects: 283
Study 19401125 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 283
Study 17712034 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexitouch (FT)
Number of subjects: 10
Study 17712034 — intervention group
Group type: EXPERIMENTAL
Intervention: Lympha Press (LP)
Number of subjects: 10
Study 14697480 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 340
Study 11477242 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging (MR imaging or CT)
Number of subjects: 145
Study 11477242 — intervention group
Group type: COMPARATOR
Intervention: No imaging
Number of subjects: 145
Study 9537455 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg of consensus interferon administered subcutaneously three times a week for 48 weeks
Number of subjects: 337
Study 9537455 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg of consensus interferon administered subcutaneously three times a week for 24 weeks
Number of subjects: 337
Study 7819467 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 2 micrograms/kg administered in 60 sec. intervals up to a total dose of 10 micrograms/kg
Number of subjects: 31
Study 7819467 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified how many patients)
Number of subjects: 31
Study 2458264 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of trypsin (150 mg h‐1; 1.25 g l‐1)
Number of subjects: 0
Study 2458264 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of aprotinin (1.5 X 10(6) KIU for 30 min)
Number of subjects: 0
Study 2458264 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of trypsin (300 mg h‐1; 2.5 g l‐1)
Number of subjects: 0
Study 30668199 — intervention group
Group type: EXPERIMENTAL
Intervention: EH301
Number of subjects: 32
Study 30668199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 28486033 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Management Training Oregon Model
Number of subjects: 0
Study 25912296 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (1‐Hz; 30 min; 1800 pulses per day for 3 weeks)
Number of subjects: 20
Study 25912296 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (same duration and frequency as active rTMS)
Number of subjects: 20
Study 25912296 — intervention group
Group type: EXPERIMENTAL
Intervention: Open label active rTMS (after initial 3 weeks of active rTMS)
Number of subjects: 20
Study 23589190 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) 20 mg/day
Number of subjects: 34
Study 23589190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 21389180 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein and moderate-carbohydrate diet (HPMC; 139 g protein, 82 g fat, 181 g carbohydrate/d)
Number of subjects: 17
Study 21389180 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein and low-carbohydrate diet (HPLC; 137 g protein, 143 g fat, 22 g carbohydrate/d)
Number of subjects: 17
Study 21389180 — intervention group
Group type: COMPARATOR
Intervention: Weight-maintenance diet (85 g protein, 116 g fat, 360 g carbohydrate/d)
Number of subjects: 17
Study 19730207 — intervention group
Group type: EXPERIMENTAL
Intervention: TDR-C (ProDisc-C, Synthes Spine)
Number of subjects: 180
Study 19730207 — intervention group
Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 180
Study 19730207 — intervention group
Group type: EXPERIMENTAL
Intervention: TDR-C and ACDF
Number of subjects: 180
Study 17410010 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose intensified chemotherapy (ICT) with filgrastim-supported sequential reinfusion of peripheral blood progenitor cells every 14 days
Number of subjects: 83
Study 17410010 — intervention group
Group type: COMPARATOR
Intervention: Standard ICE chemotherapy (SCT) every 28 days
Number of subjects: 83
Study 15285973 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care (mental health and substance abuse providers co-located in primary care; N=999)
Number of subjects: 2022
Study 15285973 — intervention group
Group type: COMPARATOR
Intervention: Enhanced referral to specialty mental health/substance abuse clinics (N=1,023)
Number of subjects: 2022
Study 15285973 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care
Number of subjects: 2022
Study 15285973 — intervention group
Group type: COMPARATOR
Intervention: Enhanced referral
Number of subjects: 2022
Study 15285973 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 2022
Study 11849198 — intervention group
Group type: EXPERIMENTAL
Intervention: SJW (0.15%) 600 mg three times daily for 16 days
Number of subjects: 22
Study 11849198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9990574 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-containing enteral feed
Number of subjects: 78
Study 9990574 — intervention group
Group type: COMPARATOR
Intervention: Control feed (isonitrogenous, isoenergetic)
Number of subjects: 78
Study 7774533 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (n = 5)
Number of subjects: 11
Study 7774533 — intervention group
Group type: COMPARATOR
Intervention: Sunflowerseed oil (n = 6)
Number of subjects: 11
Study 2185350 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of risk factors (specific interventions not detailed)
Number of subjects: 0
Study 463804 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (65% of total energy)
Number of subjects: 8
Study 463804 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (45% of total energy)
Number of subjects: 8
Study 463804 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose-containing diets (45% of total energy)
Number of subjects: 8
Study 463804 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose-containing diets (65% of total energy)
Number of subjects: 8
Study 463804 — intervention group
Group type: COMPARATOR
Intervention: Corn syrup diets (45% of total energy)
Number of subjects: 8
Study 463804 — intervention group
Group type: COMPARATOR
Intervention: Corn syrup diets (65% of total energy)
Number of subjects: 8
Study 463804 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced changes in fasting or integrated plasma cholesterol concentration
Number of subjects: 8
Study 31880006 — intervention group
Group type: EXPERIMENTAL
Intervention: ixazomib
Number of subjects: 637
Study 31880006 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 637
Study 31533105 — intervention group
Group type: EXPERIMENTAL
Intervention: Peach tree pollen (PTP) sensitisation
Number of subjects: 685
Study 31533105 — intervention group
Group type: EXPERIMENTAL
Intervention: Prunus persica 9 (Pru p 9) sensitisation
Number of subjects: 685
Study 31533105 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal provocation test (NPT)
Number of subjects: 685
Study 31533105 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms (rhinitis or rhinoconjunctivitis)
Number of subjects: 685
Study 26828264 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity treadmill walking
Number of subjects: 24
Study 26828264 — intervention group
Group type: COMPARATOR
Intervention: Light-intensity treadmill walking
Number of subjects: 24
Study 26828264 — intervention group
Group type: COMPARATOR
Intervention: High-intensity treadmill walking
Number of subjects: 24
Study 26828264 — intervention group
Group type: COMPARATOR
Intervention: Seated quiet rest
Number of subjects: 24
Study 24918473 — intervention group
Group type: EXPERIMENTAL
Intervention: painACTION.com (online pain self-management program)
Number of subjects: 0
Study 24918473 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 23352229 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (16IU)
Number of subjects: 54
Study 23352229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 21272822 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational book group
Number of subjects: 167
Study 21272822 — intervention group
Group type: COMPARATOR
Intervention: No-book group
Number of subjects: 167
Study 21272822 — intervention group
Group type: COMPARATOR
Intervention: Noneducational book group
Number of subjects: 167
Study 19595446 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-filled resin-modified GI (nano-RMGI; Ketac N100, 3M-ESPE) without primer
Number of subjects: 0
Study 19595446 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-filled resin-modified GI (nano-RMGI; Ketac N100, 3M-ESPE) with primer
Number of subjects: 0
Study 19595446 — intervention group
Group type: COMPARATOR
Intervention: Conventional RMGI restorative material (conv-RMGI; Fuji II LC, GC)
Number of subjects: 0
Study 19595446 — intervention group
Group type: COMPARATOR
Intervention: Packable conventional GI cement (conv-GI; Fuji IX GP, GC)
Number of subjects: 0
Study 17694478 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0
Study 17694478 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0
Study 17694478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15054873 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk human papillomavirus (hrHPV) testing by GP5+/6+ PCR‐enzyme immunoassay (EIA) in conjunction with cytology
Number of subjects: 44102
Study 15054873 — intervention group
Group type: COMPARATOR
Intervention: Classical cytology
Number of subjects: 44102
Study 11502643 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg vesnarinone
Number of subjects: 1046
Study 11502643 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg vesnarinone
Number of subjects: 1046
Study 11502643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1046
Study 9321777 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal sonography
Number of subjects: 68
Study 9321777 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonohysterography
Number of subjects: 68
Study 9321777 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic hysteroscopy
Number of subjects: 68
Study 8229536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin G (IVIG), 1 gm/kg per day for 2 consecutive days (n = 19)
Number of subjects: 53
Study 8229536 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone, starting at a dose of 4 mg/kg per day, tapering and discontinuation by day 21 (n = 18)
Number of subjects: 53
Study 8229536 — intervention group
Group type: COMPARATOR
Intervention: No therapy (n = 16)
Number of subjects: 53
Study 2879389 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (300 mg for 4 weeks)
Number of subjects: 0
Study 2879389 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg for 4 weeks)
Number of subjects: 0
Study 30267112 — intervention group
Group type: EXPERIMENTAL
Intervention: User- and carer-informed training package
Number of subjects: 134
Study 30267112 — intervention group
Group type: COMPARATOR
Intervention: Training intervention
Number of subjects: 134
Study 28394087 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA methylation at CpG site cg23196985
Number of subjects: 5515
Study 25319061 — intervention group
Group type: EXPERIMENTAL
Intervention: Abituzumab 500 mg combined with cetuximab and irinotecan (arm A)
Number of subjects: 216
Study 25319061 — intervention group
Group type: EXPERIMENTAL
Intervention: Abituzumab 1000 mg combined with cetuximab and irinotecan (arm B)
Number of subjects: 216
Study 25319061 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab plus irinotecan alone (SoC, arm C)
Number of subjects: 216
Study 23702231 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP (carperitide)
Number of subjects: 367
Study 23702231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study 21889560 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching group (paroxetine 20-40 mg)
Number of subjects: 132
Study 21889560 — intervention group
Group type: COMPARATOR
Intervention: Continuing group (sertraline 50-100 mg)
Number of subjects: 132
Study 19629664 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed loop stimulation (CLS)
Number of subjects: 20
Study 19629664 — intervention group
Group type: COMPARATOR
Intervention: Accelerometer (ACC)
Number of subjects: 20
Study 19629664 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed loop stimulation (CLS) and Accelerometer (ACC)
Number of subjects: 20
Study 17444378 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarised light treatment (once daily for 10 minutes on sacral area and both heels)
Number of subjects: 23
Study 17444378 — intervention group
Group type: COMPARATOR
Intervention: No polarised light treatment (control group)
Number of subjects: 23
Study 15173537 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP) after surfactant administration (SURF‐NCPAP group)
Number of subjects: 0
Study 15173537 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation (MV) after surfactant administration (SURF‐MV group)
Number of subjects: 0
Study 15173537 — intervention group
Group type: EXPERIMENTAL
Intervention: NCPAP after surfactant administration (SURF‐NCPAP group)
Number of subjects: 0
Study 11696708 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical percussion and inversion
Number of subjects: 69
Study 11696708 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 69
Study 9158092 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic vaccination with recombinant gp160 (rgp160) or gp120 (rgp120)
Number of subjects: 0
Study 9158092 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-7
Number of subjects: 0
Study 9158092 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-12
Number of subjects: 0
Study 9158092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8506453 — intervention group
Group type: EXPERIMENTAL
Intervention: Gammahydroxybutyrate (GHB), 60 mg/kg/night
Number of subjects: 24
Study 3829910 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascot preparation of procainamide hydrochloride
Number of subjects: 10
Study 3829910 — intervention group
Group type: COMPARATOR
Intervention: Squibb preparation of procainamide hydrochloride
Number of subjects: 10
Study 2575982 — intervention group
Group type: EXPERIMENTAL
Intervention: epanolol 200mg once daily
Number of subjects: 573
Study 2575982 — intervention group
Group type: COMPARATOR
Intervention: metoprolol 100mg twice daily
Number of subjects: 573
Study 2575982 — intervention group
Group type: EXPERIMENTAL
Intervention: epanolol
Number of subjects: 573
Study 2575982 — intervention group
Group type: COMPARATOR
Intervention: metoprolol
Number of subjects: 573
Study 30794316 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored text message intervention
Number of subjects: 0
Study 30601407 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating microparticles from patients with VHD before and after cardiac surgery
Number of subjects: 100